הכנסה תפעולית לפני ניכוי פחת: anbio.com (NNNN)

Intense pricing competition in the diagnostics sector is forcing Anbio Biotechnology to scale budget production. This EBITDA chart visualizes these market fluctuations, with the indicator currently standing at 6.54. While geopolitical barriers are currently hindering equipment exports, the implementation of autonomous robotic biomaterial analysis systems is significantly accelerating the interpretation of medical tests.

Analyzing EBITDA is critical for constructing a defensive portfolio, as it measures the actual cash flow from core business operations. In the case of Anbio Biotechnology (NNNN), the volume of operating cash results reflects the efficiency of mass sales of diagnostic systems and reagents to clinics, where a stable trend line confirms the company's fundamental resilience to market shocks.